Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAD51 | Q06609 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12112542 | 0.88 | PTPN1 (0.51) | ALDH1A1PTPN1PTPN2MAPTRAD51 | |
| SCHEMBL13369603 | 0.85 | PTPN1 (0.53) | ALDH1A1PTPN1PTPN2MAPTRAD51 | |
| SCHEMBL12112582 | 0.81 | PTPN1 (0.49) | ALDH1A1PTPN1PTPN2MAPTRAD51 | |
| SCHEMBL1312896 | 0.81 | CSNK2A2 (0.55) | ALDH1A1PTPN1PTPN2MAPTRAD51 | |
| SCHEMBL1147754 | 0.80 | PTPN1 (0.44) | ALDH1A1GAAPTPN1PTPN2MAPT | |
| SCHEMBL13345880 | 0.80 | PTPN1 (0.57) | ALDH1A1PTPN1PTPN2MAPTRAD51 | |
| SCHEMBL10674049 | 0.76 | ALDH1A1 (0.51) | ALDH1A1GAAMAPTKDM4EKMT2A | |
| SCHEMBL1310922 | 0.75 | PTPN2 (0.53) | ALDH1A1GAAPTPN1PTPN2KDM4E | |
| SCHEMBL1310914 | 0.72 | PTPN1 (0.56) | ALDH1A1GAAPTPN1PTPN2MAPT | |
| SCHEMBL3582281 | 0.71 | GUCY1A1 (0.55) | ALDH1A1GAAMAPTKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275646-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| US-7947682-B2 | Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-02-10 | — | — | US | disclosed |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2010-05-13 | — | — | US | disclosed |
| US-20060235034-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-10-19 | — | — | US | disclosed |
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | VEGFA, TEK, LIPG | ALDH1A1 1365/4885GAA 2608/4885PTPN1 3714/4885 |
| US-20110275646-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | VEGFA, TEK, LIPG | ALDH1A1 1365/4885GAA 2608/4885PTPN1 3714/4885 |
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | VEGFA, TEK, MCL1 | ALDH1A1 1558/4885GAA 2881/4885PTPN1 3434/4885 |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | VEGFA, TEK, MCL1 | ALDH1A1 1558/4885GAA 2881/4885PTPN1 3434/4885 |
| US-20060235034-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | VEGFA, TEK, MCL1 | ALDH1A1 1558/4885GAA 2881/4885PTPN1 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.